Skip to main content

Hematopoietic Growth Factors in Oncology

Basic Science and Clinical Therapeutics

  • Book
  • © 2004

Overview

Part of the book series: Cancer Drug Discovery and Development (CDD&D)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (22 chapters)

  1. Basic Research

  2. Hematopoietic Growth Factors

Keywords

About this book

Whether to promote platelet recovery or to ameliorate the complications of cancer and the side effects of chemotherapy, hematopoietic growth factors (HGFs) now account for more than $5 billion per year of the US health care budget. In Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics, leading oncologists, hematologists, and nephrologists comprehensively review the role of HGFs in clinical practice, explain the molecular basis of their effects, and consider potential future developments. The authors focus on the use of HGFs in oncology, describing their cutting-edge application to patients with lung cancer, Hodgkin's and non-Hodgkin's lymphoma, breast cancer, chronic lymphocytic leukemia, AIDS-related malignancies, myelodysplastic syndromes, and aplastic anemias. Among the HGFs described are granulocyte colony-stimulating factor, erythropoietc factors, thrombopoietic factors, and stem-cell factor and its receptor, c-kit. To complete their survey, the contributors also consider the safety and economic implications of HGFs and the future potential for HGF antagonists in oncology.
Comprehensive and up-to-date, Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Practice offers an integrated survey of the role of HGFs in treating and preventing anemia, neutropenia, and thrombocytopenia in patients with malignant and nonmalignant diseases, along with fresh insights into drug development and how basic discoveries in this area can be optimally translated into clinical benefit.

Reviews

"Comprehensive and up-to-date...offers an integrated survey of the role of HGFs in treating and preventing anemia, neutropenia, and thrombotopenia in patients wit malignant diseases, along with fresh insights into drug development and how basic discoveries in this area can be optimally translated into clinical benefit." - Tumori

Editors and Affiliations

  • Amgen, Australia, Pty. Ltd., Monash University, Australia

    George Morstyn

  • Amgen Inc., Thousand Oaks, USA

    MaryAnn Foote

  • Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Melbourne, Australia

    Graham J. Lieschke

Bibliographic Information

  • Book Title: Hematopoietic Growth Factors in Oncology

  • Book Subtitle: Basic Science and Clinical Therapeutics

  • Editors: George Morstyn, MaryAnn Foote, Graham J. Lieschke

  • Series Title: Cancer Drug Discovery and Development

  • DOI: https://doi.org/10.1007/978-1-59259-747-5

  • Publisher: Humana Totowa, NJ

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media New York 2004

  • Hardcover ISBN: 978-1-58829-302-2Published: 05 February 2004

  • Softcover ISBN: 978-1-4684-9847-9Published: 22 July 2012

  • eBook ISBN: 978-1-59259-747-5Published: 05 February 2004

  • Series ISSN: 2196-9906

  • Series E-ISSN: 2196-9914

  • Edition Number: 1

  • Number of Pages: X, 477

  • Topics: Hematology

Publish with us